Physicochemical and biological aspects of macrophage-mediated drug targeting in anti-microbial therapy

Fundamental and Clinical Pharmacology

Volumn 26, Issue 1, 2012, Pages 63-71

  Kunjachan, Sijumon ^a,b   Jose, Sajan ^a   Thomas, Cinu A ^a   Joseph, Emil ^c   Kiessling, Fabian ^b   Lammers, Twan ^b,d  

^a MAHATMA GANDHI UNIVERSITY   (India)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Drug targeting; Infectious disease; Leishmaniasis; Liposomes; Macrophages; Nanoparticles; Polymers

Indexed keywords

ALLOPURINOL; AMIKACIN; AMINOQUINOLINE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIBIOTIC AGENT; DOXORUBICIN; GAMMA INTERFERON; INTERFERON; LIPOSOME; MILTEFOSINE; MURAMYL DIPEPTIDE; NANOCAPSULE; NANOPARTICLE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; PRIMAQUINE;

CELL SURVIVAL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LEISHMANIA; LIVER; MACROPHAGE; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SKIN LEISHMANIASIS; SPLEEN; VISCERAL LEISHMANIASIS;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MICROBIAL; HUMANS; LEISHMANIASIS, VISCERAL; MACROPHAGES; NANOMEDICINE; PARTICLE SIZE; SCHISTOSOMIASIS; TISSUE DISTRIBUTION;

EID: 84855685585     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00955.x     Document Type: Review

References (42)

1. Kirsh R., Bugelski P.J., Poste G. Drug delivery to macrophages for the therapy of cancer and infectious diseases. Ann. N Y Acad. Sci. (1987) 507 141-154.
2. Djaldetti M., Salman H., Bergman M., Djaldetti R., Bessler H. Phagocytosis - the mighty weapon of the silent warriors. Microsc. Res. Tech. (2002) 57 421-431.
3. Ofek I., Goldhar J., Keisari Y., Sharon N. Nonopsonic phagocytosis of microorganisms. Annu. Rev. Microbiol. (1995) 49 239-276.
4. Auger M.J., Ross J.A. The biology of the macrophage, in: Lewis C.E., McGee J.O'.D. (Eds), The macrophage: The natural immune system, Oxford University Press, New York, 1992, pp. 1-74.
5. Vernon-Robert B. The macrophage, in: Harrison R.J., Mcminn R.M.H. (Eds), Biological structure and function, Vol. 2, Cambridge University Press, London, 1972, pp. 31-49.
6. Sundar S., Jha T.K., Thakur C.P. et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. (2002) 347 1739-1746.
7. Desjeux P. Leishmaniasis, public health and control. Clin. Dermatol. (1996) 14 417-423.
8. Valdir S.A., Felipe F.T., Andre M.S., Antonio C.N., Vicente A.N. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am. J. Trop. Med. Hyg. (2007) 77 266-274.
9. Sett R., Basu N., Ghosh A.K., Das P.K. Potential of doxorubicin as anti-leishmanial drug. J. Parasitol. (1992) 78 350-354.
10. Kenneth E.K., Edgar A.S., Peter S.L., William L.H., Willie L.C. Jr, Virginia B.W. The antileishmanial activity of Lepidines. Am. J. Trop. Med. Hyg. (1978) 27 751-757.
11. Sett R., Sarkar K., Ghosh A.K., Das P.K. Macrophage-directed delivery of doxorubicin conjugated to neoglycoprotein using leishmaniasis as the model disease. J. Infect. Dis. (1993) 168 994-999.
12. Basu M.K. Liposomal delivery of anti-leishmanial agents. J. Appl. Res. (2005) 5 231-236.
13. Agarwal P.K., Roca B., Sundar S., Berman J.N. Miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. (2003) 348 857-858.
14. Chaudhuri G., Mukhopadhyay A., Basu S.K. Selective delivery of drugs to macrophages through a highly specific receptor: an efficient chemotherapeutic approach against leishmaniasis. Biochem. Pharmacol. (1989) 38 2995-3002.
15. Mukhopadhyay A., Chaudari G., Arora S.K., Sehgal S., Basu S.K. Receptor mediated drug delivery to macrophages in chemotherapy of leishmaniasis. Science (2010) 44 705-707.
16. Ahsan F., Rivas I.P., Khan M.A., Torres-Suárez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control Release. (2002) 79 29-40.
17. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer (2008) 99 392-397.
18. Uchegbu I.F., Florence A.T. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv. Colloid Interface Sci. (1995) 58 1-55.
19. Drulis-Kawa Z., Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int. J. Pharm. (2010) 387 187-198.
20. Fatiha C.B., Yahye M., Alain M., L'Hocine Y. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials (2005) 26 7260-7275.
21. Muriel P., Abdelkader L., Hatem F. et al. Pentamidine-loaded poly (D, L-lactide) nanoparticles: adsorption and drug release. Drug Dev. Res. (1998) 43 98-104.
22. Kunjachan S. Targeting of Parasite Specific Doxorubicin Micro Particles for the Treatment of Experimental Visceral Leishmaniasis. (Dissertation). Department of Pharmaceutical Sciences, Mahatma Gandhi University, Kerala, India, 2007.
23. Kunjachan S., Jose S., Lammers T. Understanding the basic mechanism of ionic gelation for the synthesis of chitosan nanoparticles using qualitative techniques. Asian J. Pharm. (2010) 4 148-153.
24. Kunjachan S., Gupta S., Dwivedi A.K., Dube A., Chaurasia M.K. Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. J. Microencapsul. (2011) 28 301-310.
25. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., Greiner J.W. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine (2007) 25 2085-2094.
26. Murthy R.S.R. Biodegradable polymers, in: Jain N.K. (Eds), Controlled and novel drug delivery, CBS publishers, New Delhi, 1997, pp. 27-51.
27. Muzzaereli C. Spray drying of solutions containing solutions along with polyuronans and characterization of the microspheres. Carbohyd Polym (2001) 57 73-82.
28. Nahar M., Dubey V., Mishra D., Mishra P.K., Dube A., Jain N.K. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J. Drug Target. (2010) 18 93-105.
29. Freise J., Mtiller W.H., Magerstedt P. Uptake of liposomes and sheep red blood cells by the liver and spleen of rats with normal or decreased function of the reticuloendothelial system. Res. Exp. Med. (1981) 178 263-269.
30. Kim T.H., Jin H., Kim H.W., Cho M.H., Cho S. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol. Cancer Ther. (2006) 5 1723-1732.
31. Nallamothu R., Wood G.C., Pattillo C.B. et al. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation. AAPS PharmSciTech. (2006) 7 E1-E10.
32. Barratt G. Colloidal drug carriers: achievements and perspectives. Cell. Mol. Life Sci. (2003) 60 21-37.
33. Agrawal A.J., Agrawal A., Pal A. et al. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J. Drug Target. (2002) 10 41-45.
34. Yamamoto M., Ichinose K., Ishii N., Khoji T., Akiyoshi K., Moriguchi N. Utility of liposomes coated with polysaccharide bearing 1-amino-lactose as targeting chemotherapy for AH66 hepatoma cells. Oncol. Rep. (2000) 7 107-111.
35. Scherphof G., Velinova M., Kamps J., Donga J., Want H., Kuipers F. Modulation of pharmacokinetic behavior of liposomes. Adv. Drug Deliv. Rev. (1997) 24 179-191.
36. Gallagher J.E., George G., Brody A.R. Sialic acid mediates the initial binding of positively charged inorganic particles to alveolar macrophage membranes. Am. Rev. Respir. Dis. (1987) 135 1345-1352.
37. He C., Hu Y., Yin L., Tang C., Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials (2010) 31 3657-3666.
38. Allen T.M., Austin G.A., Chonn A., Lin L., Lee K.C. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim. Biophys. Acta (1991) 1061 56-64.
39. Mukherji S., Das K.L., Karmakar S., Datta N., Das P.K. Targeting of parasite specific immunoliposome encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis. J. Infect. Dis. (2004) 15 1024-1034.
40. Tabata Y., Ikada Y. Phagocytosis of polymer microspheres by macrophages. Adv. Polym. Sci. (1990) 94 107-141.
41. Sunder S., Gupta B.L., Rastogi V., Agrawal G., Murray H.W. Short course, cost effective treatment with amphotericin B fat emulsion cures visceral leishmaniasis. Trop. Med. Hyg. (2000) 94 200-204.
42. Tempone A.G., Perez D., Rath S., Vilarinho A.L., Mortara R.A., Andrade Jr H.F.D. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger eceptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J. Antimicrob. Chemother. (2004) 54 60-68.